Randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection.
A randomised controlled trial was conducted in 29 HBV carriers who had been HBs and HBe antigen positive for more than six months. Fifteen patients were treated with ARA-AMP 10 mg/kg/day given as intramuscular injections 12 hours apart for five days followed by 5 mg/kg/day for 23 days. The 14 controls received no treatment. Serum HBV-DNA polymerase, and HBV-DNA decreased in all patients during therapy. Six treated patients lost serum HBV-DNA polymerase, HBV-DNA and HBeAg, HBsAg concentrations decreased, and five developed anti-HBe. One of these six patients lost HBsAg and developed anti-HBs. No such changes were observed in the control group over a similar 18 month period of observation. A four week course of ARA-AMP inhibits HBV replication and in a significant minority of patients this is long lasting and is associated with a reduced level of inflammatory activity in the liver.
Weller
I V
IV
Lok
A S
AS
Mindel
A
A
Karayiannis
P
P
Galpin
S
S
Monjardino
J
J
Sherlock
S
S
Thomas
H C
HC
D000328:Adult; D001088:Arabinonucleotides / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D002986:Clinical Trials as Topic; D004279:DNA, Viral / Q000097:blood; D004259:DNA-Directed DNA Polymerase / Q000097:blood; D005260:Female; D006509:Hepatitis B / Q000097:blood / Q000188:drug therapy*; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006521:Hepatitis, Chronic / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D001084:Vidarabine Phosphate / Q000627:therapeutic use*; D014779:Virus Replication / Q000187:drug effects
D001088:Arabinonucleotides; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D001084:Vidarabine Phosphate; D001219:Aspartate Aminotransferases; D004259:DNA-Directed DNA Polymerase